CagriSema took an average 25% of body weight off women in REDEFINE 1, across every menopause stage

What happened

On 20 October 2026 Novo Nordisk presented new analyses of REDEFINE 1, its large phase 3 trial of CagriSema, at The Menopause Society's annual meeting in San Diego.

Among the 2,309 women in the trial, the 2.4 mg dose of CagriSema was linked to an average weight loss of 25% after 68 weeks. Women on placebo lost 3%. Across the whole trial of more than 3,400 adults, men included, the average was 22.7%.

By menopause stage

A second analysis looked at 1,902 women on CagriSema or placebo and split them by menopause stage. Average weight loss at week 68 was 26.7% in premenopausal women, 24.8% in perimenopausal women and 23.1% in postmenopausal women.

Many women gain weight as they move through menopause, so the question was whether the drug still worked late in that change. In these numbers the loss stayed above 23% at every stage.

How it works

CagriSema is one weekly injection with two parts. Semaglutide is the GLP-1 drug in Wegovy and Ozempic. Cagrilintide copies amylin, a hormone the pancreas releases with insulin that helps you feel full. Together they act on appetite and fullness from two directions.

What it means for you

These are analyses done after the trial met its main goals, which Novo calls hypothesis-generating. They show the drug holding above 23% average weight loss in women at every stage of menopause, a group that often finds weight harder to move.

What's next

A US FDA decision on CagriSema for weight management is expected in the fourth quarter of 2026. It is not approved yet.